April 23, 2025

FDA Targets Petroleum-Based Dyes in Food Supply

The FDA and HHS announced plans to eliminate petroleum-based synthetic food dyes, citing potential health risks and aligning with global safety standards.

Conexiant

April 17, 2025

Oral Agent Shows Weight, A1c Drops

“As a convenient once-daily pill, orforglipron may provide a new option”—Lilly's oral GLP-1 agent showed up to 7.9% weight loss and HbA1c reductions in phase III diabetes trial.

Reuters

April 14, 2025

Pfizer Halts Danuglipron Obesity Pill Trials

Pfizer discontinues development of potential weight-loss drug due to liver injury in trial participant, impacting stock prices and future strategies.

Reuters

April 11, 2025

FDA Clears Longest Lasting CGM

Dexcom G7 15 Day receives FDA clearance, offering adults with diabetes the longest lasting and most accurate continuous glucose monitoring system to date.

Conexiant

April 02, 2025

GLP-1 Spending Surged 500% Since 2018

U.S. spending on GLP-1 receptor agonists reached $71.7 billion in 2023. Semaglutide and tirzepatide products have captured 70% of the market as diabetes and weight loss medication use rapidly expands, according to new research.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 28, 2025

FDA Clears First OTC Multi-STI Test

The diagnostic test for chlamydia, gonorrhea, and trichomoniasis offers 30-minute results.

Conexiant

March 27, 2025

FDA Approves First Hyperphagia Drug for PWS

FDA approves Vykat XR as first treatment for hyperphagia in patients with Prader-Willi syndrome; decision follows extended review and long-term efficacy data.

Reuters

March 27, 2025

Simplified Tesamorelin Option for HIV Lipodystrophy

EGRIFTA WR™ has received FDA approval for use in adults with HIV and lipodystrophy to reduce excess abdominal fat with once-weekly reconstitution and a lower injection volume.

Conexiant